UY31900A - Formas solidas de ( 1r, 2s, 3r)-1-(2-(usoxazol-3-il)-1h-imidazol-4-il)butano-1, 2, 3, 4-tetraol y metodos de uso. - Google Patents

Formas solidas de ( 1r, 2s, 3r)-1-(2-(usoxazol-3-il)-1h-imidazol-4-il)butano-1, 2, 3, 4-tetraol y metodos de uso.

Info

Publication number
UY31900A
UY31900A UY0001031900A UY31900A UY31900A UY 31900 A UY31900 A UY 31900A UY 0001031900 A UY0001031900 A UY 0001031900A UY 31900 A UY31900 A UY 31900A UY 31900 A UY31900 A UY 31900A
Authority
UY
Uruguay
Prior art keywords
tetraol
imidazol
butane
methods
solid forms
Prior art date
Application number
UY0001031900A
Other languages
English (en)
Inventor
Hugh Alfred Burgoon
Suzanne Marie Buttar
Christopher Stephen Frampton
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41381634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31900(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of UY31900A publication Critical patent/UY31900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se divulgan formas sólidas de (1R, 2S, 3R)-1-(2-(isoxazol-3-il)-1H-imidazol-4-il)butano-1, 2, 3, 4-tetraol e hidratos del mismo, como así también composiciones que los contienen y métodos de uso.
UY0001031900A 2008-06-18 2009-06-16 Formas solidas de ( 1r, 2s, 3r)-1-(2-(usoxazol-3-il)-1h-imidazol-4-il)butano-1, 2, 3, 4-tetraol y metodos de uso. UY31900A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7339808P 2008-06-18 2008-06-18

Publications (1)

Publication Number Publication Date
UY31900A true UY31900A (es) 2010-01-29

Family

ID=41381634

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031900A UY31900A (es) 2008-06-18 2009-06-16 Formas solidas de ( 1r, 2s, 3r)-1-(2-(usoxazol-3-il)-1h-imidazol-4-il)butano-1, 2, 3, 4-tetraol y metodos de uso.

Country Status (20)

Country Link
US (1) US7998994B2 (es)
EP (1) EP2315765B1 (es)
JP (1) JP5550644B2 (es)
KR (1) KR20110036582A (es)
CN (1) CN102131803A (es)
AR (1) AR072153A1 (es)
AU (1) AU2009271408A1 (es)
BR (1) BRPI0914167A2 (es)
CA (1) CA2728094A1 (es)
CL (1) CL2009001436A1 (es)
CO (1) CO6341474A2 (es)
DK (1) DK2315765T3 (es)
ES (1) ES2401555T3 (es)
IL (1) IL209815A0 (es)
MX (1) MX2010013991A (es)
PE (1) PE20100085A1 (es)
RU (1) RU2011101535A (es)
TW (1) TW201004943A (es)
UY (1) UY31900A (es)
WO (1) WO2010008733A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201002698A (en) * 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
WO2011102404A1 (ja) 2010-02-18 2011-08-25 第一三共株式会社 イミダゾール誘導体
EP2586874B1 (en) 2010-06-28 2015-04-22 Daiichi Sankyo Company, Limited Method for screening for s1p lyase inhibitor using cultured cell
DE102011103751A1 (de) 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Kristallisierung von Epirubicinhydrochlorid
TW201311710A (zh) 2011-06-28 2013-03-16 Daiichi Sankyo Co Ltd 磷酸酯衍生物
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
DE4430289A1 (de) * 1993-09-04 1995-03-09 Basf Ag Verbessertes Verfahren zur Herstellung von Astaxanthin
AU2881797A (en) * 1996-05-31 1998-01-05 University Of Wollongong, The Acetyl derivatives of thiazoles and analogues
JPH1149972A (ja) * 1997-07-31 1999-02-23 Jiyun Internatl:Kk 殻廃棄物からアスタキサンチン及びキトーサンを同時に生成する方法
DK1883315T3 (da) * 2005-05-23 2011-04-11 Phares Drug Delivery Ag Direkte opløsning
EP1898928A2 (en) 2005-06-28 2008-03-19 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
ITMI20052486A1 (it) * 2005-12-23 2007-06-24 Italiana Sint Spa Procedimento di sintesi di intermedi per la preparazione di astaxantina
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200848029A (en) * 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) * 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
TW201002698A (en) * 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
CN102131504A (zh) * 2008-08-22 2011-07-20 莱西肯医药有限公司 包含双环s1p裂解酶抑制剂的组合

Also Published As

Publication number Publication date
WO2010008733A3 (en) 2010-03-25
RU2011101535A (ru) 2012-07-27
EP2315765B1 (en) 2012-12-19
US20090318516A1 (en) 2009-12-24
CN102131803A (zh) 2011-07-20
IL209815A0 (en) 2011-02-28
CA2728094A1 (en) 2010-01-21
KR20110036582A (ko) 2011-04-07
CO6341474A2 (es) 2011-11-21
JP5550644B2 (ja) 2014-07-16
CL2009001436A1 (es) 2010-10-01
BRPI0914167A2 (pt) 2015-10-20
AR072153A1 (es) 2010-08-11
AU2009271408A1 (en) 2010-01-21
DK2315765T3 (da) 2013-03-25
WO2010008733A2 (en) 2010-01-21
JP2011524915A (ja) 2011-09-08
TW201004943A (en) 2010-02-01
EP2315765A2 (en) 2011-05-04
US7998994B2 (en) 2011-08-16
PE20100085A1 (es) 2010-02-05
ES2401555T3 (es) 2013-04-22
MX2010013991A (es) 2011-01-14

Similar Documents

Publication Publication Date Title
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
ECSP10010722A (es) Compuestos orgánicos
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CR20110421A (es) Agonistas y antagonistas del receptor de s1p, y métodos de uso de los mismos
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
UY32049A (es) Inhibidores de cmet
SV2011003855A (es) Heteroarilos sustituidos
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
SV2011003800A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
UA106880C2 (uk) Нові гербіциди
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
SV2011003916A (es) Nuevas lactamas como inhibidores de beta secretasa
UY31900A (es) Formas solidas de ( 1r, 2s, 3r)-1-(2-(usoxazol-3-il)-1h-imidazol-4-il)butano-1, 2, 3, 4-tetraol y metodos de uso.
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
PA8792401A1 (es) Fenilendiaminas
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
UY31012A1 (es) Formas solidas de la oxima de la (e)-1-(4-((1r, 2s, 3r)-1,2,3,4-tetrahidroixibutil)-1h-imidazol-2-il)etanona
EA201000069A1 (ru) Новые гербициды

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181101